Contract manufacturers settle on unapproved drugs
This article was originally published in The Tan Sheet
Executive Summary
FDA bars two firms from producing and distributing unapproved, adulterated or misbranded nonprescription and Rx drugs, the agency says April 10. FDA said contract manufacturer Neilgen Pharmaceuticals, which does business as Unigen, and its parent company Advent Pharmaceuticals, each made and distributed 25 unapproved drug products, primarily prescription cough/cold products. In an April 10 release, FDA said the defendants, based in Westminster, Md., and East Windsor, N.J., will destroy their existing drugs and will not distribute new drugs without agency approval, according to a consent decree entered in federal court April 9. The firms also must retain outside experts to advise them on good manufacturing practices, the agency said
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.